India Funds Affordable COVID-19 Vaccine Candidate Using Dyadic's Platform
Dyadic International Inc's (NASDAQ:DYAI) licensee, Epygen Biotech PVD, LTD., has received funding from the Government of India to advance an affordable COVID-19 vaccine candidate through Phase 1 and Phase 2 trials. Epygen's COVID-19 vaccine utilizes Dyadic's C1 protein production platform. Epygen Biotech is an Indian Biopharmaceutical company engaged in research and manufacturing therapeutic proteins…
Benzinga ·
Benzinga
